Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin
- 31 December 1989
- journal article
- Published by Elsevier in Advances in Enzyme Regulation
- Vol. 28, 335-356
- https://doi.org/10.1016/0065-2571(89)90080-0
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemiaAdvances in Enzyme Regulation, 1988
- IMP dehydrogenase: Inhibition by the anti-leukemic drug, tiazofurinLeukemia Research, 1988
- Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenaseBiochemistry, 1988
- Inosine monophosphate dehydrogenase activity in acute leukaemiaLeukemia Research, 1987
- The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory propertiesBiochemical Pharmacology, 1982
- Guanosine-5′-phosphate synthetase and guanosine-5′-phosphate kinase in rat hepatomas and kidney tumorsBiochimica et Biophysica Acta (BBA) - Enzymology, 1981
- Role of ribonucleotide reductase in expression of the neoplastic programLife Sciences, 1981
- Inosine 5?-phosphate dehydrogenase activity in normal and leukemic blood cellsJournal of Molecular Medicine, 1979
- Partial purification, properties and regulation of inosine 5′-phosphate dehydrogenase in normal and malignant rat tissuesBiochemical Journal, 1977
- Key enzymes of IMP metabolism: Transformation- and proliferation-linked alterations in gene expressionAdvances in Enzyme Regulation, 1976